The Master Protocol for Biomarker-Integrated Umbrella Trial in Advanced Gastric Cancer
Latest Information Update: 30 Oct 2023
At a glance
- Drugs Nivolumab (Primary) ; Paclitaxel (Primary) ; Afatinib; GSK 2636771; Ramucirumab
- Indications Gastric cancer; Oesophageal cancer
- Focus Adverse reactions; Biomarker; Therapeutic Use
- 26 Oct 2023 Primary endpoint has not been met. (maximum tolerated dose (MTD) and recommended phase II dose (RP2D) for phase 1b), as per Results published in the Journal of Clinical Oncology
- 26 Oct 2023 Primary endpoint has not been met. (progression free survival), as per Results published in the Journal of Clinical Oncology
- 26 Oct 2023 Results published in the Journal of Clinical Oncology